China's Central Bank Announces Rate Cut, Injects Liquidity
China's central bank has lowered a short-term policy rate and pumped more liquidity into the financial system, as it continues efforts to help boost the economy.
The People's Bank of China cut the 14-day reverse repurchase interest rate by 10 basis points to 1.85%, and injected 74.5 billion yuan ($10.6 billion) of liquidity via the policy tool, it said on its website on Monday.
The latest cut is a reflection of the reduction in the 7-day reverse repo rate in July, during which the PBOC didn't conduct a 14-day reverse repo operation, said Zhiwei Zhang, an economist at Pinpoint Asset Management.
The central bank also injected CNY160.1 billion through 7-day reverse repo agreements, keeping the interest rate unchanged at 1.7%, it said Monday.
Last week, the PBOC unexpectedly held its benchmark lending rates steady, despite rising expectations for easing following the U.S. Federal Reserve's own rate cut.
Economists anticipate the Chinese central bank will lower its 7-day reverse repo rate--now seen as the key rate for pricing benchmark lending rates--in the coming months, as the Fed's cut gives it more room for monetary policy easing.
Write to Singapore editors at singaporeeditors@dowjones.com
(END) Dow Jones Newswires
September 22, 2024 22:53 ET (02:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk